<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab2">
 <label>Table 2</label>
 <caption>
  <p>Description of studies included in review</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Author/Country</th>
    <th>Population/Study design</th>
    <th>Exposures</th>
    <th>Comparators</th>
    <th>Treatments</th>
    <th>TB occurrence</th>
    <th>SARS-CoV/MERS/COVID-19 Severity rate/Time</th>
    <th>SARS-CoV/MERS-CoV/COVID-19 Recovery rate/Time</th>
    <th>Mortality rate</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>
     <p>Liu 2006</p>
     <p>China [
      <xref ref-type="bibr" rid="CR29">29</xref>]
     </p>
    </td>
    <td>
     <p>-Three males of 48(case 1), 18 (case 2) and 20 years (case 3) old with confirmed SARS-CoV</p>
     <p>-case series</p>
    </td>
    <td>
     <p>PTB</p>
     <p>SARS-CoV</p>
    </td>
    <td>N/A</td>
    <td>
     <p>Corticosteroids</p>
     <p>mechanical ventilation</p>
     <p>Anti TB drugs</p>
    </td>
    <td>PTB diagnosed while case 1 was in the hospital. Case 2 and 3 were known TB on treatment.</td>
    <td>Two patients developed mild SARS-CoV and one developed severe stage.</td>
    <td>All of them recovered form SARS-CoV and continue anti-TB drugs</td>
    <td>N/A</td>
   </tr>
   <tr>
    <td>
     <p>Low 2004</p>
     <p>Singapore [
      <xref ref-type="bibr" rid="CR30">30</xref>]
     </p>
    </td>
    <td>
     <p>-Two males of 54 and 39 years old with confirmed SARS-CoV</p>
     <p>-Case series</p>
    </td>
    <td>
     <p>PTB</p>
     <p>SARS-CoV</p>
    </td>
    <td>N/A</td>
    <td>
     <p>intravenous immunoglobulin</p>
     <p>short course of high-dose corticosteroids</p>
     <p>Anti TB drugs</p>
    </td>
    <td>PTB developed after four and 2 months prior to SARS-CoV.</td>
    <td>Both of them developed severe SARS-CoV</td>
    <td>Both of the cases recovered from SARS-CoV</td>
    <td>N/A</td>
   </tr>
   <tr>
    <td>
     <p>Wong 2004</p>
     <p>Hong Kong [
      <xref ref-type="bibr" rid="CR31">31</xref>]
     </p>
    </td>
    <td>
     <p>-30 years old male with confirmed SARS-CoV and HIV on ART</p>
     <p>-Case report</p>
    </td>
    <td>
     <p>HIV</p>
     <p>Latent TB</p>
     <p>SARS-CoV</p>
    </td>
    <td>N/A</td>
    <td>
     <p>Abacavir 300 mg Efavirenz 600 mg Kaletra Tenofovir 300 mg</p>
     <p>Ribavirin 1200 mg prednisolone 25 mg</p>
    </td>
    <td>Diagnosed with PTB during hospitalization</td>
    <td>Mild course SARS</td>
    <td>The case recovered from SARS-CoV</td>
    <td>N/A</td>
   </tr>
   <tr>
    <td>
     <p>Alfaraj 2017</p>
     <p>Kingdom of Saudi Arabia [
      <xref ref-type="bibr" rid="CR32">32</xref>]
     </p>
    </td>
    <td>
     <p>−13-year-old girl and A 30-year-old female with confirmed MERS-CoV</p>
     <p>-Case series</p>
    </td>
    <td>
     <p>PTB</p>
     <p>MERS-CoV</p>
    </td>
    <td>N/A</td>
    <td>
     <p>intensive care admission</p>
     <p>Anti TB drugs</p>
    </td>
    <td>Both patients initially had TB before MERS-CoV</td>
    <td>The 13 years old had severe MERS-CoV. However, the disease severity was moderate with the 30 years old.</td>
    <td>Both of the cases recovered from MERS-CoV</td>
    <td>N/A</td>
   </tr>
   <tr>
    <td>
     <p>Singh 2020</p>
     <p>India [
      <xref ref-type="bibr" rid="CR33">33</xref>]
     </p>
    </td>
    <td>
     <p>76-year- old female with confirmed COVID-19</p>
     <p>Case study</p>
    </td>
    <td>
     <p>PTB</p>
     <p>COVID-19</p>
    </td>
    <td>N/A</td>
    <td>
     <p>hydroxychloroquine 400 mg twice daily in addition to antibiotics.</p>
     <p>Anti TB drugs</p>
    </td>
    <td>Diagnosed with TB during admission</td>
    <td>Mild to moderate COVID-19</td>
    <td>The patient recovered from COVID-19</td>
    <td>N/A</td>
   </tr>
   <tr>
    <td>
     <p>He 2020</p>
     <p>China [
      <xref ref-type="bibr" rid="CR34">34</xref>]
     </p>
    </td>
    <td>
     <p>All three patients were males with 26, 67 and 76 years</p>
     <p>-Case series</p>
    </td>
    <td>
     <p>Previous TB PTB</p>
     <p>COVID-19</p>
    </td>
    <td>N/A</td>
    <td>
     <p>Lopinavir + Ritonavir</p>
     <p>Arbidol</p>
     <p>Methyl prednisolone</p>
     <p>Antibiotics</p>
     <p>Traditional Chinese medicine</p>
     <p>Intravenous immunoglobulin</p>
     <p>Ventilatory support</p>
     <p>Antituberculosis</p>
    </td>
    <td>Past medical history of TB years ago for all the three patients</td>
    <td>
     <p>All of them had severe type of COVID-19</p>
     <p>10 days after onset for the first symptom</p>
    </td>
    <td>All of the three cases recovered from COVID-19</td>
    <td>N/A</td>
   </tr>
   <tr>
    <td>
     <p>Cutler 2020</p>
     <p>USA [
      <xref ref-type="bibr" rid="CR35">35</xref>]
     </p>
    </td>
    <td>
     <p>61-year-old male with confirmed COVID-19 and history of Parkinson’s disease.</p>
     <p>Case study</p>
    </td>
    <td>
     <p>PTB</p>
     <p>COVID-19</p>
    </td>
    <td>N/A</td>
    <td>
     <p>Hydroxychloroquine</p>
     <p>Oxygen supplementation</p>
     <p>Anti-TB drugs</p>
    </td>
    <td>TB diagnosed in hospitalization</td>
    <td>Critical COVID-19 stage</td>
    <td>Recovered for COVID-19</td>
    <td>N/A</td>
   </tr>
   <tr>
    <td>
     <p>Çınar 2020</p>
     <p>Turkey [
      <xref ref-type="bibr" rid="CR36">36</xref>]
     </p>
    </td>
    <td>
     <p>55-year-old male with a history of myelodysplastic</p>
     <p>Syndrome, immunocompromised, kidney failure and confirmed with COVID-19</p>
     <p>Case study</p>
    </td>
    <td>
     <p>Disseminated TB</p>
     <p>COVID-19</p>
    </td>
    <td>N/A</td>
    <td>
     <p>COVID-19 convalescent plasma</p>
     <p>Favipiravir</p>
     <p>meropenem</p>
     <p>Ventilatory support</p>
     <p>Anti-TB drugs</p>
    </td>
    <td>TB diagnosed in hospitalization</td>
    <td>Critical COVID-19 stage</td>
    <td>Recovered for COVID-19</td>
    <td>N/A</td>
   </tr>
   <tr>
    <td>
     <p>Faqihi 2020</p>
     <p>Saudi Arabia [
      <xref ref-type="bibr" rid="CR37">37</xref>]
     </p>
    </td>
    <td>
     <p>60 year-old male, hypertensive and diabetic, with confirmed COVID-19</p>
     <p>Case study</p>
    </td>
    <td>
     <p>PTB</p>
     <p>COVID-19</p>
    </td>
    <td>N/A</td>
    <td>
     <p>Lopinavir/ritonavir Ribavirin Dexamethasone Prophylactic anticoagulation Supportive ICU care</p>
     <p>Anti-TB drugs</p>
    </td>
    <td>Previous TB history</td>
    <td>Critical COVID-19 stage</td>
    <td>Recovered for COVID-19 after 20 days</td>
    <td>N/A</td>
   </tr>
   <tr>
    <td>
     <p>Liu 2020a</p>
     <p>China [
      <xref ref-type="bibr" rid="CR38">38</xref>]
     </p>
    </td>
    <td>
     <p>48 year-old, 26-year-old and 46-year-old males with confirmed COVID-19/TB co-infection</p>
     <p>Case series</p>
    </td>
    <td>
     <p>PTB</p>
     <p>COVID-19</p>
    </td>
    <td>N/A</td>
    <td>
     <p>Arbidol</p>
     <p>Moxifloxacin</p>
     <p>Linezolid</p>
     <p>immunomodulatory therapy with thymopentin</p>
     <p>Ventilatory support</p>
     <p>Anti-TB drugs</p>
    </td>
    <td>The first and the last case had LTBI and the second was a previous MDR-TB</td>
    <td>All of them developed severe/critical COVID-19 courses</td>
    <td>All of them recovered from COVID-19 with the range of 9 to 14 days</td>
    <td>N/A</td>
   </tr>
   <tr>
    <td>
     <p>Tham 2020</p>
     <p>Singapore [
      <xref ref-type="bibr" rid="CR39">39</xref>]
     </p>
    </td>
    <td>
     <p>32-year-old, 33-year-old, 22-year old and 40-year old males COVID-19/TB co-infected patients</p>
     <p>Case series</p>
    </td>
    <td>
     <p>PTB</p>
     <p>COVID-19</p>
    </td>
    <td>N/A</td>
    <td>
     <p>COVID-19 antiviral drugs</p>
     <p>Anti-TB drugs</p>
    </td>
    <td>N/A</td>
    <td>N/A</td>
    <td>All of them recovered.</td>
    <td>N/A</td>
   </tr>
   <tr>
    <td>
     <p>Stochino 2020</p>
     <p>Italy [
      <xref ref-type="bibr" rid="CR40">40</xref>]
     </p>
    </td>
    <td>
     <p>20 confirmed cases of COVID-19/TB co-infection. Among them, one case was also HIV-infected. The median age was 39 years</p>
     <p>Case series</p>
    </td>
    <td>
     <p>PTB</p>
     <p>Disseminated TB</p>
     <p>COVID-19</p>
    </td>
    <td>N/A</td>
    <td>
     <p>Hydroxychloroquine.</p>
     <p>Ventilatory support</p>
     <p>Anti-TB drugs</p>
    </td>
    <td>N/A</td>
    <td>
     <p>7 out of 20 developed severe/critical COVID-19</p>
     <p>13 out of 20 developed mild/moderate COVID-19</p>
     <p>Average of 32 [range 14–57] days</p>
    </td>
    <td>19 out of 20 patients recovered.</td>
    <td>1 patient died.</td>
   </tr>
   <tr>
    <td>
     <p>Chen 2020</p>
     <p>China [
      <xref ref-type="bibr" rid="CR28">28</xref>]
     </p>
    </td>
    <td>
     <p>Only four cases of COVID-19/TB co-infection were included in a cohort of 203 confirmed COVID-19 cases.</p>
     <p>Case series</p>
    </td>
    <td>
     <p>PTB</p>
     <p>COVID-19</p>
    </td>
    <td>Survivors vs deceased</td>
    <td>N/A</td>
    <td>N/A</td>
    <td>N/A</td>
    <td>N/A</td>
    <td>1 case out of 4 died.</td>
   </tr>
   <tr>
    <td>
     <p>Du 2020</p>
     <p>China [
      <xref ref-type="bibr" rid="CR41">41</xref>]
     </p>
    </td>
    <td>
     <p>8 confirmed cases of COVID-19/TB</p>
     <p>prospective cohort study</p>
    </td>
    <td>
     <p>PTB</p>
     <p>COVID-19</p>
    </td>
    <td>Survivors vs deceased</td>
    <td>N/A</td>
    <td>N/A</td>
    <td>N/A</td>
    <td>N/A</td>
    <td>
     <p>COVID-19/TB: 0/8</p>
     <p>COVID-19: 21/171</p>
    </td>
   </tr>
   <tr>
    <td>
     <p>Davies 2020</p>
     <p>South Africa [
      <xref ref-type="bibr" rid="CR42">42</xref>]
     </p>
    </td>
    <td>
     <p>3978 COVID-19/HIV co-infected patients</p>
     <p>18,330 COVID-19 infected patients, public sector patients aged ≥20 years.</p>
     <p>Population prospective cohort study</p>
    </td>
    <td>
     <p>Previous TB status</p>
     <p>Latent TB</p>
     <p>HIV</p>
     <p>COVID-19</p>
    </td>
    <td>COVID-19/HIV/TB vs COVID-19/TB</td>
    <td>
     <p>Antiretroviral therapy</p>
     <p>Anti-TB</p>
     <p>COVID-19 antiviral therapies</p>
    </td>
    <td>
     <p>COVID-19/HIV/TB current TB: 172/3863</p>
     <p>Previous TB: 864/3863</p>
     <p>COVID-19/TB</p>
     <p>current TB: 145/ 17,820</p>
     <p>Previous TB: 10/510</p>
    </td>
    <td>N/A</td>
    <td>
     <p>COVID-19/HIV/TB: 1039/1094</p>
     <p>COVID-19: 2827/2884</p>
     <p>COVID-19/TB: 979/1034</p>
     <p>COVID-19: 16841/17296</p>
    </td>
    <td>
     <p>COVID-19/HIV/TB</p>
     <p>Current TB: 16/172</p>
     <p>Previous TB: 42/864</p>
     <p>COVID-19/TB</p>
     <p>Current TB: 10/145</p>
     <p>Previous TB: 45/834</p>
     <p>COVID-19/HIV/TB: 58/1034</p>
     <p>COVID-19/HIV: 57/2884</p>
     <p>COVID-19/TB: 55/1034</p>
     <p>COVID-19: 455/17296</p>
    </td>
   </tr>
   <tr>
    <td>
     <p>Karla 2020</p>
     <p>Philipines [
      <xref ref-type="bibr" rid="CR43">43</xref>]
     </p>
    </td>
    <td>
     <p>The matched sample 4510 consisted of COVID-19 patients, of which 113 had confirmed TB. The mean age of the total sample was 48.9 years</p>
     <p>Longitudinal matched cohort analysis</p>
    </td>
    <td>Confirmed TB, which was defined as a history of or a current diagnosis of TB.</td>
    <td>COVID-19/TB co-infection vs COVID-19/no TB</td>
    <td>N/A</td>
    <td>N/A</td>
    <td>
     <p>Admitted in the hospital</p>
     <p>COVID-19/TB: 67/106</p>
     <p>COVID-19: 236/424</p>
    </td>
    <td>
     <p>COVID-19/TB</p>
     <p>Recovered: 57 /106</p>
     <p>COVID-19</p>
     <p>Recovered: 302/424</p>
    </td>
    <td>
     <p>COVID-19/TB</p>
     <p>Died: 25 /106</p>
     <p>COVID-19 Died: 46/ 424</p>
    </td>
   </tr>
   <tr>
    <td>
     <p>Liu 2020</p>
     <p>China [
      <xref ref-type="bibr" rid="CR38">38</xref>]
     </p>
    </td>
    <td>
     <p>−36 confirmed COVID-19 cases</p>
     <p>Among which 13 were IGRA+ve to TB, mean age: 47 years</p>
     <p>Case-control study</p>
    </td>
    <td>
     <p>Previous TB status</p>
     <p>Latent TB</p>
     <p>COVID-19</p>
    </td>
    <td>Case series study of 115 bacterial and 62 other viral pneumonia. Controls selected in the same setting.</td>
    <td>N/A</td>
    <td>
     <p>Previous TB: 8/13</p>
     <p>Current TB: 3/13</p>
    </td>
    <td>
     <p>Severity:</p>
     <p>Mild/Moderate:</p>
     <p>0/27</p>
     <p>Severe/Critical: 3/9</p>
     <p>-severe/critical COVID-19: 3.4 days after initial symptom development.</p>
    </td>
    <td>N/A</td>
    <td>N/A</td>
   </tr>
   <tr>
    <td>
     <p>Li 2020</p>
     <p>China [
      <xref ref-type="bibr" rid="CR2">2</xref>]
     </p>
    </td>
    <td>
     <p>A total of 549 patients with COVID-19 were enrolled. The median age of study population was 60 years.</p>
     <p>Retrospective study</p>
    </td>
    <td>
     <p>PTB</p>
     <p>COVID-19</p>
    </td>
    <td>Non-Severe vs severe COVID-19</td>
    <td>N/A</td>
    <td>N/A</td>
    <td>
     <p>Severe: 4/269</p>
     <p>Not severe: 5/ 279</p>
    </td>
    <td>N/A</td>
    <td>N/A</td>
   </tr>
   <tr>
    <td>
     <p>Zhang 2020</p>
     <p>China [
      <xref ref-type="bibr" rid="CR44">44</xref>]
     </p>
    </td>
    <td>
     <p>−140 confirmed COVID-19 cases, 2 of whom had secondary PTB</p>
     <p>-Retrospective study</p>
    </td>
    <td>
     <p>PTB</p>
     <p>COVID-19</p>
    </td>
    <td>Non-severe vs Severe COVID-19</td>
    <td>N/A</td>
    <td>N/A</td>
    <td>
     <p>Severity COVID-19/TB Severe: 2/58</p>
     <p>Not severe: 0/82</p>
    </td>
    <td>N/A</td>
    <td>N/A</td>
   </tr>
   <tr>
    <td>
     <p>Zhang 2020b</p>
     <p>China [
      <xref ref-type="bibr" rid="CR44">44</xref>]
     </p>
    </td>
    <td>
     <p>1350 confirmed cases of COVID-19 among which 8 were COVID-19/TB co-infected cases.</p>
     <p>Age (44.1 ± 17.9) years</p>
     <p>Retrospective cohort study</p>
    </td>
    <td>
     <p>PTB</p>
     <p>COVID-19</p>
    </td>
    <td>Non-severe vs Severe COVID-19</td>
    <td>N/A</td>
    <td>N/A</td>
    <td>
     <p>Severe: 3/229</p>
     <p>Not severe: 2/1121</p>
    </td>
    <td>N/A</td>
    <td>N/A</td>
   </tr>
   <tr>
    <td>
     <p>Motta 2020</p>
     <p>Italy, Belgium, Brazil, France, Russia, Singapore, Spain, Switzerland [
      <xref ref-type="bibr" rid="CR47">47</xref>]
     </p>
    </td>
    <td>
     <p>- 49 confirmed TB and COVID-19 cases, median age 70 years</p>
     <p>Retrospective cohort study</p>
    </td>
    <td>
     <p>Previous TB status</p>
     <p>Latent TB</p>
     <p>COVID-19</p>
     <p>One patient with HIV</p>
    </td>
    <td>
     <p>20 confirmed COVID-19/TB cases</p>
     <p>Retrospective cohort study (Cohort B)</p>
    </td>
    <td>
     <p>Hydroxychloroquine</p>
     <p>Lopinavir/ ritonavir</p>
     <p>Azythromycin</p>
     <p>Empiric antibiotic</p>
     <p>Enoxaparine 4000 IU</p>
     <p>Dexamethasone</p>
     <p>Oxygen through non-rebreather, 15lt/min</p>
     <p>Anti TB drugs</p>
    </td>
    <td>
     <p>−3 with previous TB diagnosed</p>
     <p>−8 (simultaneous diagnosis of COVID-10 and TB</p>
     <p>−11 had COVID-19 diagnosed between 7 and 75 days) after the TB diagnosis</p>
    </td>
    <td>
     <p>−5 patients had severe COVID-19</p>
     <p>− 8 patients developed critical COVID-19</p>
     <p>-Critical COVID-19: median of 9 (range 6–14) days after</p>
     <p>COVID-19 diagnosis</p>
    </td>
    <td>60 cases recovered from COVID-19/TB co-infection the both cohorts.</td>
    <td>9 out of 69 died from COVID-19/TB co-infection</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
